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ABSTRACT 
The bacterium Stenotrophomonas maltophilia is an emerging infectious pathogen of 
global concern. Due to its drug-resistant nature, there are limited treatment options available. A 
potential option for combating S. maltophilia infections is phage therapy, the medicinal use of 
viruses to treat bacterial infections. Stenotrophomonas phage Bfi1 was isolated from a soil 
sample using S. maltophilia clinical strain S18202. Transmission electron microscopy provided 
evidence that this phage is a member of the Siphoviridae family. Host range analysis showed that 
the phage successfully infected and lysed 30% of the S. maltophilia strains tested. Genomic 
analysis revealed that the phage contains approximately 32.2-56.5 kbp dsDNA. This phage was 
assessed for its ability to affect biofilm formation. At an MOI≥103, the phage inhibited S18202 
biofilm formation after 24 h incubation with the phage. To the best of our knowledge, this is the 
first time the effects of a bacteriophage on S. maltophilia biofilms have been studied. 
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I. INTRODUCTION 
Stenotrophomonas maltophilia: An Opportunistic Pathogen 
Stenotrophomonas maltophilia is a species with a complex taxonomic history. This species of 
bacteria was first described in 1943 by J.L. Edwards (Hugh and Ryschenkow, 1961). At the 
time, the species was named Bacterium bookeri (Hugh and Ryschenkow, 1961). Since its 
original characterization, it was reclassified as Pseudomonas maltophilia due to its physiological 
characteristics, including multitrichous flagella (Hugh and Ryschenkow, 1961). Later, the 
species was classified as a Xanthomonas sp. (Swings et al., 1983). The authors cited DNA-rRNA 
hybridization data, among other genotypic and phenotypic characteristics, as major influences 
for this reclassification. Because of the unique phenotypes of P. maltophilia, adding it to the 
taxonomic group, Xanthomonas, altered the definition of this genus (Palleroni and Bradbury, 
1993). To resolve this conflict, a new bacterial genus, Stenotrophomonas, was named; this is 
where S. maltophilia is currently classified. This history is important as earlier publications use 
these different names in their work. Additionally, it demonstrates the relatedness of S. 
maltophilia to other bacterial pathogens, such as Pseudomonas aeruginosa or Xanthomonas 
campestris, a human and plant pathogen, respectively. 
S. maltophilia is found throughout the world (Brooke, 2012). There is evidence that the 
species can live in a wide range of moist environments. It has been isolated from many 
environments, including plant roots and soil, river water, tap water, vertebrates, and invertebrates 
(Nakatsu et al., 1995; Denton et al., 2003; Hejnar et al., 2007; Romanenko, 2008; Berg, 2009). 
Its ability to live in diverse environments makes it a concern, because there are many sources 
from which an infection can be acquired. While nosocomial infections are common, a review of 
several studies from various health networks (United States, Australia, Taiwan, Canada, 
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Germany) estimated that 22 % of S. maltophilia infection cases are community-acquired 
(Falagas et al., 2009). 
This bacterium is an opportunistic pathogen. This means it is not highly infectious, but it 
can cause disease in humans when the normal host barriers have been penetrated (Brooke, 
2012). S. maltophilia causes diseases in patients with compromised immune systems, such as 
patients with cancer or cystic fibrosis (CF) (Chang et al., 2015). It has been the causative agent 
of bacteremia, biliary sepsis, meningitis, and urinary tract infections, among other infections 
(Nguyen and Muder, 1994; Papadakis et al., 1995; Vartivarian et al., 1996; Araoka et al., 2010). 
In general, these infections are life-threatening. In one hospital survey of S. maltophilia 
infections, the reported mortality rate was 60% (Nseir et al., 2006). 
As a pathogen, evidence indicates that S. maltophilia is a growing concern. SENTRY 
Antimicrobial Surveillance Program studies show that over time the prevalence rates of        
S. maltophilia respiratory tract infections (RTIs) increased from 3.3%-3.5% during 1997-2004 
to 4.4% during 2009-2012 (Gales et al., 2001; Hoban et al., 2003; Jones, 2010; Sader et al., 
2014). These studies showed that S. maltophilia moved from the eighth most common cause 
of RTIs to the sixth in the United States. Additionally, of non-enteric Gram-negative bacilli, 
S. maltophilia ranks globally as the third most commonly isolated pathogen from any 
infection (Sader and Jones, 2005). These data demonstrate that S. maltophilia should not be 
overlooked, because a significant number of infections result from this pathogen with 
increasing frequency. 
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Use of Antibiotics 
The primary treatment for S. maltophilia infections is antibiotic therapy. Currently healthcare 
professionals recommend trimethoprim-sulfamethoxazole (TMP-SMX) (Chang et al., 2015). 
This antibiotic is used primarily because resistance to TMP-SMX is not common. One 
surveillance study (2009-2012) found that 96% of US isolates and 98% of European isolates 
were susceptible to TMP-SMX (Sader et al., 2014). For patients with contraindications for TMP-
SMX, the fluoroquinolone levofloxacin is recommended (Chang et al., 2015). There are concerns 
that the efficacy of levofloxacin is not as high as TMP-SMX. However, two retrospective studies 
reported no statistical difference in outcome between these two antibiotic approaches (Cho et al., 
2014; Wang et al., 2014). These two antibiotics are currently considered to be effective therapies 
for S. maltophilia infections. 
Despite the efficacy of levofloxacin and TMP-SMX, there are long-term concerns with 
antibiotic therapy. Worldwide susceptibility of S. maltophilia to levofloxacin has decreased 
from 83.4 % (2003-2008) to 77.3% (2011) (Farrell et al., 2010; Sader et al., 2013). Additionally, 
resistance to TMP-SMX has been identified (Toleman et al., 2007). As S. maltophilia infection 
rates increase, one can expect that antibiotic resistance will rise. 
 
Antibiotic Resistance Genes of S. maltophilia 
S. maltophilia is naturally resistant to many antibiotics. It has been suggested that this natural 
resistance may arise from selection pressures that arise from a plant commensal lifestyle. High 
levels of competition and exposure to natural antibiotics and secondary antimicrobial metabolites 
are strong evolutionary drivers that contribute to this resistance (Berg and Martinez, 2015).  
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Within the genome of S. maltophilia, the genes that facilitate the breakdown or removal 
of antibiotics play a major role in antibiotic resistance. L1 and L2 are β-lactamases encoded in 
the S. maltophilia genome (Crossman et al., 2008). L1 hydrolyses all β-lactams except aztreonam 
(a monobactam) (Paton et al., 1994). L2 hydrolyses all penicillins, all cephalosporins in the first, 
second and third generations, and aztreonam (Walsh et al., 1997). Several aminoglycoside-
modifying enzymes have been described in S. maltophilia strains. These enzymes include 
AAC(6’)Iz, APH(3’)-IIc, AAC(6’)-Iak, and AAC(6’)-Iam (Li et al., 2003; Okazaki and Avison, 
2007; Crossman et al., 2008; Tada et al., 2014). Drug efflux pumps also play a major role in 
antibiotic resistance. A recent analysis of the genome of S. maltophilia K279a identified four 
efflux pumps involved in antibiotic resistance: SmeABC SmeDEF, SmeIJK, and SmeYZ 
(Alonso and Martinez, 2000; Li et al., 2002; Crossman et al., 2008). These efflux pumps 
contribute to resistance of a broad range of antibiotics, including β-lactams, aminoglycosides, 
quinolones, tetracyclines, macrolides, chloramphenicol, novobiocin, and TMP-SMX (Wang et 
al., 2018). 
While some resistance mechanisms involve the breakdown or effluxion of antibiotics, the 
S. maltophilia genome also contains genes whose encoded proteins resist the mechanisms of 
action of antibiotics. The sul2 gene encodes for a dihydropteroate synthase which is not 
inhibited by sulfonamides. Strains that have class 1 integrons and insertion sequence common 
region elements that were linked to the gene sul2 are resistant to TMP-SMX (Toleman et al., 
2007). Sulfonamides, like sulfamethoxazole ,work by binding to the active site of 
dihydropteroate synthase, which is involved in folic acid synthesis, converting p-aminbenzoate 
to dihydropteroic acid. The sul2 codes for a dihydropteroate synthase that has a weak binding 
affinity for sulfonamides (Sköld, 2000). Variants of dfr genes, that code for dihydrofolate 
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reductase, are also associated with high levels of resistance to TMP-SMX (Hu et al., 2011). 
Dihydrofolate reductase is an enzyme involved in DNA synthesis. Trimethoprim binds to 
dihydrofolate reductase to inhibit its function. Variants in the dfr genes lead to weaker binding 
by this enzyme to trimethoprim and consequently lead to resistance to this drug (Sköld and 
Widh, 1974). 
The chromosomal qnr gene has been associated with quinolone resistance in 
S. maltophilia. Quinolones target DNA gyrase, an enzyme that relieves tension of supercoiling 
during DNA replication (Champoux, 2001). The antibiotic forms a stable complex with the DNA 
and DNA gyrase, preventing the progression of DNA replication (Hiasa and Shea, 2000). The 
qnr gene encodes a protein that can bind specifically to the gyrase holoenzyme in the DNA 
binding groove. This prevents the deleterious effects of the stabilized quinolone, DNA, and 
DNA gyrase complex (Hooper and Jacoby, 2015). By doing so, Qnr has demonstrated its 
importance in low-level resistance to quinolones (Sánchez and Martínez, 2010). 
Resistance to polymyxins can be attributed to the gene, spgM. This gene encodes a 
phosphoglucomutase involved in lipopolysaccharide (LPS) synthesis. Bacterial mutants that lack 
spgM have less LPS when compared to SpgM+ cells (McKay et al., 2003). Polymyxin selectively 
binds to LPS and destabilizes the outer membrane enough to penetrate. Ultimately, the antibiotic 
causes lysis of the host by destroying the integrity of the cell’s inner membrane (Yu et al., 2015; 
Malinowski et al., 2017). With less LPS, there are fewer targets for the antibiotic’s action. 
 
Biofilms of S. maltophilia 
Along with possessing antibiotic resistance genes, S. maltophilia can form biofilms. A biofilm is 
an accumulation of microbial cells that are associated with a surface and enclosed in a 
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polysaccharide matrix (Donlan, 2002). Biofilms are formed when, individual, free-floating cells 
(referred to as planktonic cells), adhere to a surface. The cells replicate, form a monolayer, and 
begin to secrete a polysaccharide matrix (extracellular polymeric substance) outside of the cell 
(Gupta et al., 2016). S. maltophilia can form biofilms on a variety of surfaces. S. maltophilia can 
form biofilms on glass, plastics, and host tissue (Jucker et al., 1996; de Oliveira-Garcia et al., 
2003). 
Biofilms have been shown to facilitate antibiotic resistance in two ways. First, 
extracellular polymeric matrices act as a physical barrier. For example, extracellular matrix 
components in P. aeruginosa biofilms can impede penetration of the antibiotic ciprofloxacin 
into cells living within the biofilm (Suci et al., 1994). The biofilm acts to shield the cells within 
the structure. 
The second mechanism of biofilm resistance relates to variation in the cell populations of 
a biofilm. Because cells in a biofilm have access to differing nutrient levels, there is 
heterogeneity in the cellular metabolic rates within the population (Burrowes et al., 2011). Some 
cells with little nutrient access exist in slow-growing or starved states. These are referred to as 
persister cells. Since antibiotics often target the pathways involved in actively growing and 
dividing cells, persister cells are not affected by these antimicrobials (Costerton et al., 1999). 
 
Bacteriophages 
The ability for S. maltophilia to persist, despite antibiotic treatments has led to a need for 
alternative therapies, and directed an interest in the research of bacteriophages. Often referred 
to as phages, they are defined as viruses that infect a bacterial host (Labrie et al., 2010). They 
usually come in two forms, lytic (or virulent) and lysogenic (or temperate). Upon infection by a 
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lytic phage, the virus takes over the host’s machinery and replicates itself (Labrie et al., 2010). 
At the end of the lytic cycle, the host cell is lysed to release viral progeny (Labrie et al., 2010). 
When a temperate phage infects their host, the phage DNA is incorporated into the 
genome of the host, becoming a prophage (Labrie et al., 2010). Inside the host, the virus can 
remain dormant and is transmitted vertically to host daughter cells (Labrie et al., 2010). Under 
certain conditions, the prophage can be activated via induction to enter into a lytic cycle and lyse 
the host cell (Labrie et al., 2010). 
A third, less common form of phage infection is known as pseudolysogeny. During 
pseudolysogeny, the infection of the host is stalled. The viral nucleic acids do not replicate as it 
would in a lytic cycle or integrate as it would in a lysogenic cycle (Ripp and Miller, 1997). It is 
present in the host in an inactive state. 
Lytic phages have drawn a lot of interest from researchers concerned with antibiotic 
resistance. Because the lytic cycle is inherently lethal to the bacterial host, physicians could 
potentially use phages to treat and prevent bacterial infections in humans. Prior to the discovery 
of antibiotics, phages were documented as being used in the treatment of infections (Abedon et 
al., 2011). This legacy has continued in several countries in Western Europe, including Georgia 
and Poland (Abedon et al., 2011). 
Phage therapies may offer many advantages over antibiotic therapies. A major benefit is 
that phages have a limited effect on resident flora. Phages usually only infect organisms of the 
same species. The breadth of strains or species which can be infected by a virus is referred to as 
the viral host range. The fact that many phages are shown to have limited host ranges means the 
killing of off-target bacteria is minimized (Abedon et al., 2011). This results in a lower potential 
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for side effects brought about by dysbiosis, the disturbance to gut microbiota homeostasis 
(DeGruttola et al., 2016). 
The abundance of phages is another benefit to be considered. Estimations by phage 
ecologists have determined that the number of phage particles found in soil is on average 1.5 x 
108 g-1 (Ashelford et al., 2003). In aquatic environments, it has been estimated that there are 
approximately 100-300 phage strains ml-1 (Wommack et al., 1999). This means that there are 
potentially many undescribed phages in these habitats that have yet to be assessed for 
therapeutic use. In the case that a bacterial pathogen develops resistance to one phage, there are 
many other phages that may cause host lysis. 
 
S. maltophilia Phages 
To the best of our knowledge, there have been six lytic and pseudolysogenic S. maltophilia 
bacteriophages described in the literature to date. Of the described lytic phages, four are 
myoviruses, phiSMA5 (Chang et al., 2005), Smp14 (Chen et al., 2007), and S3 (García et al., 
2008), DLP6 (Peters et al., 2017), one is a podovirus, IME15 (Huang et al., 2012), and one is a 
siphovirus DLP2 (Peters et al., 2015). Each of these phages has a double stranded (ds) DNA 
genome. At the time of writing, these reported phages represent the entire library of phages with 
potential to be used in treatments for S. maltophilia infections. 
The first lytic phage to be characterized was phiSMA5 (Chang et al., 2005). The phage 
was determined to have a dsDNA genome that is ~250 kbp and contains at least 25 proteins 
(Chang et al., 2005). Smp14 was the first phage to have its genome partially sequenced (Chen et 
al., 2007). The genome is estimated to be ~160 kbp and consists of at least 20 unique proteins. 
Phage S3 was found to have a genome of ~33 kbp (García et al., 2008). The DNA of phage S3 
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was resistant to digestion by restriction enzymes, which suggests that it might contain atypical 
bases or be enzymatically modified. IME15 was the first phage to have its full genome 
sequenced, with a genome of ~39 kbp. The second potentially lytic phage to have its whole 
genome sequenced was DLP2 with a genome of ~42 kbp in size (Peters et al., 2015). The final 
phage described was DLP6. This T4-like phage undergoes pseudolysogeny prior to lytic 
activation. The phage genome does not integrate into the host DNA, but proceeds into the lytic 
cycle following activation. The genome of DLP6 was sequenced and found to be ~168 kbp 
(Peters et al., 2017). 
The first step in this thesis research was to isolate a Stenotrophomonas phage from an 
environmental sample. Upon isolation, the phage was characterized using molecular and 
microbiological techniques. At the time of writing, this thesis research provides the first 
assessment of a Stenotrophomonas phage’s effect on its bacterial host’s biofilm. Using an in 
vitro model of biofilm formation in the presence or absence of phage, we hypothesized that the 
presence of phage significantly inhibits biofilm formation by S. maltophilia 
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II. METHODS 
Maintenance and Growth of Bacteria  
S. maltophilia S18202 was grown and stored on LB (Luria-Bertani) agar. S. maltophilia cultures 
were prepared by growing them overnight in LB broth at 37°C with shaking at 235 rpm. Cultures 
were standardized to OD600   1.0. Dilutions of culture were added to fresh LB broth and 
incubated with agitation at 37°C until exponential growth was obtained (2h). Overnight cultures 
were used for phage isolation, plaque enumeration assays, biofilm assays, and host range spot 
tests. 
 
Isolation of Bacteriophage 
Soil samples were taken from landscaping mulch on the north side of the William G. McGowan 
Building on the DePaul University Lincoln Park campus, in Chicago, Illinois. A 10 g sample of 
the soil was added to 15 ml of a modified LB suspension medium (SM) (Peters et al., 2015). 
After mixing for 1 h on a Stovall Belly Dancer (IBI Scientific) at room temperature (25C), the 
sample was centrifuged at 12,000 x g at 25C to remove excess soil debris. The supernatant was 
filter sterilized (0.45 m pore size). One hundred microliters of an overnight culture of               
S. maltophilia S18202 was added to the filtrate, and was incubated at 37C overnight (Van Twest 
and Kropinski, 2009). The mixture was then centrifuged at 12,000 x g for 5 min at 25C. The 
liquid supernatant was filter sterilized (0.45 m pore size) and stored at 4C. This preparation 
was used as a phage stock for plaque purification.  
 
 11 
Plaque Purification 
To purify the virus, a soft agar overlay of the phage sample was performed according to 
Kropinski et al. (2009) with modifications from Peters et al. (2015). In microfuge tubes, a 200 l 
preparation of S. maltophilia was added to 100 l of phage from a serial dilution of the phage 
stock. The virus and bacteria were incubated statically for 8-10 min at 25C. The phage-bacteria 
mixture was added to 4 ml of molten soft LB agar (0.4% agar). This was gently swirled and 
poured over an LB agar plate. After the soft agar was allowed to solidify, the plates were 
incubated at 37C overnight. A single plaque was picked from a plate with isolated plaques by 
touching a sterile glass pipette tip to it. The pipette tip was immersed in 500 l of SM with 20 l 
of chloroform for 1 h statically at 25C. The chloroform was used to kill any living bacteria 
present in the sample. The plaque isolation and purification steps were repeated two subsequent 
times to obtain purified phage. The plaque purified stock was used to prepare a high titer stock. 
 
Preparation of High Titer Phage 
A soft agar overlay plate with a confluent lawn of plaques (obtained after overnight incubation) 
was selected to make the phage stock. Ten milliliters of SM was added to the plate. The plate 
was gently agitated on a Stovall Belly Dancer for 1 h. The SM was then removed and added to 
microfuge tubes. The tubes were centrifuged at 12,000 x g at 25C for 2 min and the supernatant 
was filter sterilized (0.45 m pore size). The purified high titer phage stock was stored at 4C. 
This stock was used for the enumeration of the phage. For long-term storage of phage stocks, 
purified phage was prepared in 50% glycerol/SM and stored at –80C according to Fortier and 
Moineau (2009). 
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Enumeration of Phage 
Phage titer determination used the soft agar overlay technique and a serial dilution of the high 
titer purified phage stock (Kropinski et al., 2009). To a set of microfuge tubes, 200 l of            
S. maltophilia was mixed with 100 l of serially diluted phage stock. The samples were 
incubated statically for 8-10 min at 25C. The mixture of phage and bacteria was transferred to a 
test tube containing 4 ml of molten soft LB agar. The tube contents were then poured over a plate 
of LB agar and allowed to solidify. The plates were incubated at 37C overnight. The number of 
plaques was recorded and the original concentration of phage stock was determined according to 
Equation 1. 
 
Equation 1 
 
 
𝑝𝑙𝑎𝑞𝑢𝑒 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠
𝑚𝑙
=  
(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ×  # 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑝𝑒𝑟 𝑝𝑙𝑎𝑡𝑒)
𝑝𝑙𝑎𝑡𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒
  
 
Determining Plaque Size 
A plaque assay was performed (see Enumeration of Phage). Plates were incubated overnight at 
37 C. The plates were then digitally photographed with a 50 mm ruler for reference. Images of 
plaques on a lawn of S. maltophilia S18202 were analyzed using tpsDig software (by F. James 
Rohlf, Stony Brook Morphometrics).  
 
Transmission Electron Microscopy 
The ultrastructure of the phage was analyzed using the Imaging Facility at the Loyola University 
Chicago Health Sciences Campus, Maywood, Illinois. Carbon-coated 200 mesh copper grids 
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(Ted Pella, Inc) were treated with 0.002% Alcian Blue in 0.03% acetic acid (Electron 
Microscopy Sciences) for 5 min then incubated with distilled water for 5 min to increase the 
hydrophilicity of the grids (Chattoraj et al., 1988). Grids were incubated with a high titer sample 
of phage (2 x 1011 pfu/ml) in SM for 1 min then stained with filtered 1% uranyl acetate for 1 
min.  A Philips CM120 transmission electron microscope (voltage = 80 kV) equipped with an 
AMT BioSprint camera was used to image the samples. Images of 15 phage particles were used 
to acquire measurements of phage ultrastructure. Tail length, tail width, and head diameter were 
measured using ImageJ (Schneider et al., 2012). 
 
Phage DNA Analysis 
S. maltophilia phage DNA was extracted using the Phage DNA Isolation Kit according to the 
manufacturer’s instructions (Norgen Biotek Corporation) and stored at -20°C. The concentration 
of purified DNA was determined using a NanoDrop 2000c (Thermo Scientific). Phage DNA was 
subjected to restriction enzyme digestion (Table 1). Type II restriction enzymes were used due to 
their ability to digest dsDNA. To prepare each restriction enzyme digest, approximately 150-200 
ng of DNA were used. The phage DNA digests were subjected to agarose gel electrophoresis at 
80V for about 1 h and then visualized using a FlourChem HD2 system (Bio-Techne). Alphaview 
software (Bio-Techne) was used to analyze the DNA digests.  
Table 1: Restriction enzymes used  
BglII PvuII 
ClaI SalI 
EcoRI SmaI  
KpnI SphI 
PstI XhoI 
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Host Range Analysis 
The host range analysis of the S. maltophilia phage was performed according to García et al. 
(2008) with the following modifications. The bacterial strains used for the tests are listed in 
Table 2. The clinical strains of S. maltophilia were kindly provided by Dr. Stanford Shulman 
(Northwestern University). Lawns (confluent growth) of each strain on LB agar plates were 
prepared using overnight cultures. Four 5 l drops of phage (~109 pfu/ml) were placed on top of 
each agar plate. Plates were incubated at 37C overnight and the presence of clearings were 
recorded . Each bacterium was tested in two independent experiments.  
 
Table 2: Bacterial strains used  
for host range tests 
S. maltophilia  
ATCC 13637 H2138 
ATCC 17807 H43306 
ATCC BAA-2423 H59296 
F64644 S18202 
F7221 X26332 
P. aeruginosa  E. coli  
ATCC 27853 ATCC 23922 
ATCC 22580 S. aureus  
ATCC BAA-47 ATCC 29213 
 
Biofilm Assays 
To determine if the purified S. maltophilia phage inhibited biofilm formation of S. maltophilia 
S18202, biofilm assays were performed according to Malinowski et al. (2017) with the following 
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modifications. After determining the phage titer (see Enumeration of Phage), a dilution was 
made to achieve a multiplicity of infection (MOI) of 10, 103, or 105. The MOI is a measure of the 
ratio of the number of plaque-forming units to number of colony-forming units (pfu/cfu). To 
each well of a 96-well polyvinyl chloride (PVC) microtiter plate (BD Falcon), 50 l of phage in 
SM (10mM MgSO4, 50mM Tris-HCl pH 7.5, 100mM NaCl, 50% LB) diluted in LB broth were 
added. Fifty microliters of S. maltophilia culture were added to each well. Negative control wells 
contained 100 l of LB broth only (no cells or phage). Biofilm plates were incubated statically 
for 24 h at 37C. Planktonic cells were removed to a new microtiter plate and the bacterial 
culture density was recorded using a spectrophotometer (OD595). Adhered biofilms were washed 
twice with sterile distilled water (dH2O), stained with 0.1% crystal violet for 10 min, washed 
three times with sterile dH2O, and air dried overnight at room temperature with minimal light 
exposure. The crystal violet was thoroughly resuspended in 30% acetic acid and the amount of 
biofilm was recorded at OD560. 
When performing the experiments at the MOIs of 10 and 105, each biofilm assay was 
performed once, with 5 and 4 replicates, respectively. For the experiment at the MOI of 103, the 
biofilm assay was performed in two independent experiments, each with 5 replicates.  
 
Statistical Analysis 
In all the biofilm assays, we used a paired t-test to compare means of each treated subculture 
with the untreated subculture. The α-values were adjusted using the sequential Bonferroni test 
(Holms, 1979). Statistical analyses were performed using Microsoft Excel.  
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III RESULTS 
Isolation of a S. maltophilia Phage 
A S. maltophilia phage was isolated from soil acquired from a horticultural flower bed adjacent 
to McGowan North, on DePaul University – Lincoln Park campus. In soft agar overlays of S. 
maltophilia S18202 with phage after overnight incubation at 37°C, the phage produced clear 
plaques. The size of the plaques ranged from 0.5 – 2.0 mm in diameter (Figure 1). Some plaques 
had surrounding halos that were turbid in appearance (Figure 2). The plaque purified phage was 
named Stenotrophomonas virus Bfi1 (Biofilm formation inhibitor 1). 
 
 
Figure 1: Phage plaques formed on a lawn of S. maltophilia S18202. The plate was incubated at 
37C overnight on LB agar with a 10-8 dilution of the phage stock. Scale bar = 50 mm. 
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Figure 2: Plaque morphology of isolated phage Bfi1. Black arrows highlight plaques with turbid 
halos. White arrows highlight plaques without halos. Scale bar = 2 mm.  
 
 
Bfi1 Ultrastructure 
Ultrastructure morphological examination revealed that the phage has a head and an unsheathed 
flexible non-contractile tail (Figure 3). The head has an isometric icosahedral shape, with a 
diameter of 50.8 ± 5.7 nm. The tail length measures 197.0 ± 31.7 nm. The tail width measures 
10.4 ± 1.7 nm.  
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Figure 3: Transmission electron micrograph of Stenotrophomonas phage Bfi1, negatively stained 
with 1% uranyl acetate. Scale bar = 100 nm.  
 
Phage Genome Analysis 
Restriction enzyme (RE) digestion followed with agarose gel electrophoresis demonstrated that 
the S. maltophilia phage contains dsDNA. RE analysis of the DNA showed 5 of the 10 type II 
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restriction enzymes were able to digest the phage genome: EcoRI, KpnI, SalI, SmaI, and SphI 
(Figure 4).  
 
Figure 4: Agarose gel (1%) electrophoresis showing single RE digests of Stenotrophomonas 
phage DNA. Lanes: (1) 1 kbp marker, (2) uncut phage DNA, (3) EcoRI, (4) KpnI, (5) SalI, (6) 
SmaI, (7) SphI, (8)  phage HindIII marker. 
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Digestion of the genome by type II restriction enzymes (EcoRI, KpnI, SalI, SmaI, and 
SphI) produced large, well-separated DNA bands (Table 3). Using the AlphaView software to 
analyze the DNA fragments, the size of the phage genome was estimated to be 32.2-56.5 kbp. 
This was done by adding the fragment sizes of each band from individual digests to get a total 
DNA size.  
 
Table 3: Bfi1 single RE digest DNA sizes 
Band 
DNA fragment length (bp) 
EcoRI KpnI SalI SmaI SphI 
1 19027 19027 7067 8083 9833 
2 14377   7800 5800 5000 8833 
3   6800   7000 4333 4700 7467 
4   5550   6267 3825 4267 6467 
5   4567   5700 1550 3725 5400 
6   2833   2307 1447 3211 3625 
7   1950 - 1340 2409 2648 
8   1436 - 1048 2307 2027 
9 - -   936 2170 1858 
10 - -   801 1517 1583 
11 - -   736 1000 1330 
12 - -   656   881 1074 
13 - -   594   771   949 
14 - -   534   588   831 
15 - -   458   460 - 
16 - -   402   428 - 
17 - -   366   306 - 
18 - -   314 - - 
Total  56540 48101  32207     41823    53925 
 
Host Range Analysis 
The host range of this phage was assessed using available strains of S. maltophilia,                     
P. aeruginosa, Escherichia coli, and Staphylococcus aureus (Table 4 and Figure 5). Of the 
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bacteria tested, 30% of the S. maltophilia strains (S18202, H2138, H43306) were infected by the 
phage (as indicated by phage generated clearings formed within the lawn of bacteria), and the 
remainder of the bacteria were resistant to infection (as indicated by the absence of clearings). 
These observations indicate that S. maltophilia phage Bfi1 has a moderate host range.  
 
Table 4. Host range of Bfi1 
Bacterial strain Infection by phage* 
S. maltophilia   
ATCC 13637 - 
ATCC 17807 - 
ATCC BAA-2423 - 
F64644 - 
F7221 - 
H2138 + 
H43306 + 
H59296 - 
S18202 + 
X26332 - 
P. aeruginosa   
ATCC 27853 - 
ATCC 22580 - 
ATCC BAA-47 - 
E. coli   
ATCC 23922 - 
S. aureus   
ATCC 29213 - 
* + phage infection, -  no infection 
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Figure 5: Bfi1 spot tests of S. maltophilia strains. (A) Strain H2138 shows infectivity and (B) 
strain H59269 shows no infectivity by the phage. 
 
Phage Inhibition of S. maltophilia Biofilm Formation 
Following a 24 h incubation of S18202 in a microtiter plate, liquid medium containing 
planktonic cells was removed and the cell density of the media quantified by spectrophotometry 
(OD595). At an MOI=10 (actual MOI≈5.1) a significant inhibition of planktonic cell culture 
density was observed (Figure 6A). Inhibition of planktonic cell growth was also observed at an 
MOI=103 (actual MOI≈1.8x103) and an MOI=105 (actual MOI≈1.5x105) (Figure 6B, C).  
The amount of biofilm formed on the microtiter plate surface was determined using the 
crystal violet assay. The difference in the amount of biofilm formed was not statistically 
significant at MOI=10 (Figure 7A). At MOI=103 and MOI=105, the amount of biofilm formed 
was significantly reduced in the phage treatment groups (Figure 7B, C).  
 
A B 
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Figure 6: Planktonic cell culture density (OD595) of S. maltophilia after 24 h treatment with 
phage Bfi1, (A) MOI=10 (B) MOI=103 (C) MOI=105 . Vertical bars represent standard error.  
(*) indicates statistical significance of paired t-tests adjusted using a sequential Bonferroni test 
for multiple comparisons. (A) p = 2.1 x 10-2, (B) p = 5.7 x 10-8, (C) p = 1.1 x 10-3  
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Figure 7: Amount of biofilm formed (OD560) of S. maltophilia after 24 h treatment with phage 
Bfi1, (A) MOI=10 (B) MOI=103 (C) MOI=105 . Vertical bars represent standard error.  
(*) indicates statistical significance of paired t-tests adjusted using a sequential Bonferroni test 
for multiple comparisons. (A) p = 0.75, (B) p = 5.9 x 10-4, (C) p = 1.2 x 10-3 
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IV. DISCUSSION 
S. maltophilia Bacteriophage Bfi1 
S. maltophilia bacteriophage, Bfi1, was successfully isolated from a local soil sample. Initially, 
plaques were harvested and purified. The purified phage was further characterized using 
transmission electron microscopy, and its genome was analyzed using restriction enzyme 
digestion with agarose gel electrophoresis.  
 
Plaque Morphology 
Phage Bfi1 was able to form circular plaques, ranging from 0.5 – 2.0 mm in diameter (Figure 1). 
Plaque size is affected by a variety of factors including the virus’s diffusivity, adsorption rate, 
latent period, and burst size (Abedon and Yin, 2009; Gallet et al., 2011). Diffusivity is a measure 
of the capability for a particle to be diffused. Adsorption rate is the rate at which plaque-forming 
units attach to susceptible host cells. The latent period is the infection time, between adsorption 
and host cell lysis. Burst size is defined as the number of new plaque-forming units produced 
when an infected cell lyses. The variation in plaque size within a single phage strain may be due 
to subtle differences in the genotypes that resulted from random mutations during replication. 
These differences could affect the burst size, adsorption rate, latent period and diffusivity of the 
phage. 
Some phages can reduce biofilms by producing enzymes that break up extracellular 
polymers. These enzymes, called depolymerases have been shown to be important in biofilm 
penetration (Casey et al., 2018). One indicator that a phage may possess a depolymerase is 
through analysis of plaque morphology. The plaques of depolymerase-expressing phages are 
often surrounded by a large halo, which indicates depolymerase activity (Hughes et al., 1998). 
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Since there were halos surrounding some of the phage derived plaques (Figure 2), S. maltophilia 
phage Bfi1 may produce depolymerases. 
 
Ultrastructure of Bfi1 
Table 5 shows the ultrastructural diversity of bacteriophages. One third of the phages shown 
contain a tail. Tailed phages (Order: Caudovirales) are considered the most abundant phages 
found in nature (Ackermann, 2007). Of ~5500 phages documented using electron microscopy 
and submitted to the Félix d’Hérelle Reference Center for Bacterial Viruses, 96% of them were 
described as tailed phages (Ackermann, 2007). The phage tail is an appendage that is used in 
host receptor recognition, penetration of the cell wall and ejection of the virus genome into the 
host cell (Fokine and Rossman, 2014). 
The Caudovirales order is divided into four families, Ackermannviridae, Myoviridae, 
Podoviridae, and Siphoviridae (Ackermann, 2009; Adriaenssens et al., 2018) Morphologically, 
Ackermannviridae and Myoviridae are indistinguishable, both possessing long sheathed 
contractile tails (Adriaenssens et al., 2018). Podoviridae possess short stubby non-contractile 
tails. Long unsheathed flexible non-contractile tails are a hallmark of the Siphoviridae family 
(Ackermann, 2009).  
We compared the tail ultrastructure of 15 Bfi1 virions to the four families of 
Caudovirales. The tail length of Bfi1 is 197.0 ± 31.7 nm , which is much longer than the tail 
length of Podoviridae phages (20 nm) (King et al., 2012). Therefore, it is unlikely that Bfi1 
belongs to Podoviridae. The tail width of Bfi1 is 10.4 ± 1.7 nm. This falls within the description 
of Siphoviridae phages, which have tail widths of 7-10 nm (King et al., 2012). The tail widths of 
Myoviridae and Ackermannviridae phages (16-20 nm) are much thicker than the tail of Bfi1 
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(King et al., 2012). When considering that Bfi1 also has a flexible tail (Figure 3), our 
observations lead us to conclude that Bfi1 is most likely a member of the Siphoviridae family 
within the Caudovirales order. 
 
 
 
Table 5: Overview of bacteriophage families 
Family Description of Ultrastructure Nucleic Acid 
 
Myoviridae 
 
long sheathed contractile tail 
length: 80-455 nm; width:16-20 nm 
 
 
dsDNA linear 
Ackermannviridae long sheathed contractile tail 
length: 80-455 nm; width: 16-20 nm 
 
dsDNA linear 
Siphoviridae long unsheathed flexible non-contractile tail 
length: 65-570 nm; width: 7-10 nm 
 
dsDNA linear 
Podoviridae short non-contractile tail 
length: 20 nm; width: 8 nm 
 
dsDNA linear 
Tectiviridae 
 
isometric, double capsid dsDNA linear 
Corticoviridae 
 
isometric capsid dsDNA circular 
Plasmaviridae 
 
enveloped, no capsid, pleomorphic dsDNA circular 
Sphaerolipoviridae 
 
isometric capsid dsDNA linear 
Inoviridae 
 
long filaments or short rods ssDNA circular 
Microviridae 
 
conspicuous capsomers, isometric capsid ssDNA circular 
Leviviridae 
 
isometric capsid ssRNA linear 
Cystoviridae 
 
enveloped, spherical dsRNA segmented 
(Ackermann, 2009; King et al., 2012; Adriessens et al., 2018) 
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S. maltophilia Phage Bfi1 Genome  
The Caudovirales order is additionally unique in that their dsDNA is linear (Ackermann, 
2009). This appears to be a result of the virion structure. To package DNA into a capsid and eject 
the genome from it, the DNA must be threaded through a narrow passage in the head portal. This 
passage is too small to accommodate two parallel dsDNAs simultaneously (as would be needed 
in the case of a circular genome) (Casjens and Gilcrease 2009). As S. maltophilia phage Bfi1 
appears to be a member of the Caudovirales order, we can infer that the phage in this study is 
likely to have a linear genome.  
The type II restriction enzyme digestions of the S. maltophilia phage Bfi1 genome 
indicate that the phage genome is dsDNA, as these enzymes are only able to cut this type of 
nucleic acid (Figure 4). Restriction enzyme analysis determined the size of the genome to 32.2-
56.5 kb (Table 3). A more accurate determination of the size would result from fully sequencing 
the genome. Genomic sequencing can be done using a shotgun cloning protocol (Lynch et al., 
2010).  
Without genomic sequencing, this DNA analysis did not generate enough information for 
us to conclusively identify the novelty of this phage. According to the International Committee 
on the Taxonomy of Viruses (ICTV), the major basis for distinguishing a new species of virus 
requires evidence that its genome sequence identity be less than 95% similar to its closest 
taxonomic relative (Adriaenssens and Brister, 2017). Until the genome of this phage is 
sequenced, the Bacterial and Archaeal Virus Subcommittees within the ICTV will not be able to 
affirm the novelty of this phage.  
Taken together, the ultrastructure and genome analyses of S. maltophilia phage Bfi1 
support its classification as a siphovirus within the Caudovirales order.  
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S. maltophilia Siphoviruses 
At the time of writing, Bfi1 is the sixth Siphoviridae phage to be characterized that 
infects S. maltophilia. Table 6 describes all S. maltophilia siphoviruses described in the 
literature. 
Table 6: S. maltophilia siphoviruses 
Phage 
Head Diameter 
(nm) 
Tail Length 
(nm) 
Tail Width 
(nm) 
Genome 
size (kbp) 
Reference 
S1 61.4 ± 1.35 129.2 ± 1.3 9.93 ± 0.66 40.287 García et al., 2008 
S4 87.5 ± 1.5 201.87 ± 1.22 10.7 ± 0.24 ~200 García et al., 2008 
DLP1 ~70 ~175 NA 42.887 Peters et al., 2015 
DLP2 ~70 ~205 NA 42.593 Peters et al., 2015 
DLP5 NA NA NA 96.542 Peters and Dennis, 2018 
Bfi1 50.8 ± 5.7 197.0 ±31.7 10.4 ± 1.7 32.2-56.5 This study 
     *NA, not available 
 
García et al. (2008) reported two temperate siphoviruses that have a S. maltophilia host, 
S1 and S4. S1 was discovered by induction of a lysogen using mitomycin C. S4 was acquired 
from sewage samples. Peters et al. (2015) identified two S. maltophilia siphoviruses, DLP1 and 
DLP2. DLP1 was isolated from river sediment DLP2 was isolated from soil. DLP1 has a unique 
plaque development; at high titers (1010 pfu/ml) no plaques form. At lower titers, plaques were 
turbid with no distinct borders. DLP2 produces plaques with distinct borders. Neither phages 
contain any recognizable lysogeny-associated proteins in its genome. However, due to the 
irregular plaque formation, DLP1 is likely a lysogenic phage. Based on this data, DLP2 might be 
lytic, but this has not been confirmed experimentally. As of the writing of this thesis, there is not 
much information available on DLP5, but it was shown to be lysogenic (Peters and Dennis, 
2018). 
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In comparing Bfi1 to other siphoviruses, we can see that our phage appears similar to 
others in tail size and length, while it has a smaller head diameter (Table 6). There is a large 
range of genome sizes for S. maltophilia siphoviruses, but Bfi1 falls within this range. With the 
current data, it is not possible to determine if Bfi1 is lytic or lysogenic. However, it is possible 
that this represents the first lytic  S. maltophilia siphovirus to be described.  
Lysogenic abilities can be assessed by characterizing the phage genome. Lysogeny-
associated proteins, such as integrases and lytic cycle repressors are often readily identifiable 
(Casey et al., 2018). Lysogeny can also be tested experimentally by taking colonies that acquire 
phage resistance and testing the host genome for the presence of a prophage.  
 
Host Range of Bfi1 
The process of host cell lysis involves the adsorption of the phage to the host receptor (Labrie et 
al., 2010). After adsorption, the phage genome is ejected into the host. Replication of the phage 
genome and virion structure occurs during the latent period. Lysis occurs at the end of infection 
and viral progeny are released into the surrounding media (Labrie et al., 2010). The progeny 
viruses start the infection process over in neighboring host cells. Eventually enough cells are 
killed that a clearing is visible to the naked eye. The exact timing of this process, can be 
determined by performing a one-step growth assay. This can be useful information when looking 
at lytic activity of a phage and is an important feature of phage characterization.  
The first step in the phage infection cycle, adsorption, is the initial point of contact 
between virus and host and dictates host range specificity (Silva et al., 2016). Caudovirales 
phages recognize hosts using their tail structures, which have phage receptor-binding proteins 
(RBPs) which can recognize specific peptide sequences or polysaccharide moieties (Silva et al., 
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2016). A phage fails to effectively infect a strain when the host receptors are inaccessible or non-
complementary to the phage RBPs (Silva et al., 2016). Of Siphoviridae phages studied with 
Gram-negative bacterial hosts, 16 recognized proteinaceous receptors and 3 required a 
combination of proteins and sugar moieties (Silva et al., 2016). 
The moderate host range of 30% for S. maltophilia phage Bfi1 is based on only 10 strains 
of S. maltophilia (Table 4). Because the number of strains tested in this research was relatively 
small, it may not be reflective of the true host range of this phage. Ideally, we would develop an 
expansive S. maltophilia collection, containing a variety of pathogenic strains which would 
represent a breadth of genetic diversity within this species. 
The host ranges of other Stenotrophomonas lytic phages are highlighted in Table 7. These 
host ranges could all be described as moderate, ranging from 30% to 70% of strains tested. It 
should be remarked that DLP2 formed plaques on two P. aeruginosa strains as well (Peters et al., 
2015). The ability of the mentioned phages to infect hosts from different taxonomic orders is not 
typical. 
 
Table 7: Host range of lytic and pseudolysogenic S. maltophilia phages 
Phage  Family Host Range Strains Tested       Reference 
phiSMA5 Myoviridae 70% 10 Chang et al., 2005 
Smp14 Myoviridae 56% 87 Chen et al., 2007 
S3 Myoviridae 46% 26 García et al., 2008 
DLP2 Siphoviridae 33% 27 Peters et al., 2015 
DLP6 Myoviridae 48% 27 Peters et al., 2017 
Bfi1 Siphoviridae 30% 10 This Study 
 
The limited host range of S. maltophilia phages might be attributed to the considerable 
diversity of this host species. In comparing the genome of ATCC BAA-2423 (K279a, a 
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pathogenic strain) to R551-3 (a plant endosymbiotic strain), approximately 85% of the R551-3 
strain’s 4,175 genes were homologous to the pathogenic strain (Ryan et al., 2009). This leaves 
hundreds of divergent genes between these two strains. Even between pathogenic isolates there is 
considerable diversity. A study of 139 S. maltophilia isolates from the same hospital found that 
there was considerable phylogenetic and phenotypic variability between isolates (Valdezate et 
al., 2004). If host susceptibility can be blocked by modifications to a single receptor gene, then 
the diversity within the species S. maltophilia may explain the limits to the host range of these 
Stenotrophomonas phages. 
The type of host receptor that is recognized by S. maltophilia phage Bfi1 has not been 
determined. Understanding the host receptors needed for phage infection of Stenotrophomonas 
maltophilia may be informative in understanding why the host range is moderate. This could be 
tested by developing a mutant library of S18202 and determining which gene(s) is/are necessary 
for phage infection. 
Host receptor recognition is not the only component of host range specificity, but it is a 
major avenue to acquire resistance against viral infections (Rodriguez-Valera et al., 2009). 
Bacterial hosts can employ a variety of other mechanisms to block phage infection. These 
include: superinfection exclusion systems, restriction-modification systems, Argonaute proteins, 
CRISPR-Cas systems, abortive infection systems, and toxin-antitoxin systems (Dy et al., 2014). 
S. maltophilia phage Bfi1 was tested against P. aeruginosa, a related pathogen (Williams 
et al., 2010). Based on observations by Peters et al. (2015) we know that there are some phages 
that infect both S. maltophilia and P. aeruginosa. There are limited examples of phages with this 
wide of a host range, so we did not expect to observe plaque formation by Bfi1 on P. aeruginosa. 
Regardless of our expectations, it is medically relevant to test this because P. aeruginosa and    
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S. maltophilia are often found together in polymicrobial communities (Berg et al., 2005). Most 
notably these bacteria can coinfect the CF patient’s lungs (Graff and Burn, 2002).  
Other organisms that are phylogenetically related to Stenotrophomonas maltophilia, may 
also be susceptible to phage Bfi1, including those of the Xanthomonas and Xylella genera 
(Williams et al., 2010). Both these genera harbor debilitating plant pathogens of agricultural 
significance, such as black rot (affecting cruciferous vegetables like cabbage and broccoli) 
(Williams, 1980) and Pierce’s disease (a lethal grapevine disease) (Hopkins and Purcell, 2002). It 
may be significant to consider the effect of Bfi1 on these pathogens due to their economic and 
agricultural harm. 
 
Phage-Biofilm Interactions 
To the best of our knowledge, this is the first time the effects of a phage on S. maltophilia 
biofilms have been studied. From the biofilm assays, we demonstrated that the phage, at an 
MOI=103, inhibits the development of biofilms when it is introduced simultaneously with 
planktonic cells in culture (Figure 7B). This effect is even greater at MOI=105 (Figure 7C). At 
MOI=10 there was only a small effect on the planktonic cell culture of the bacteria (Figure 6A). 
There is no effect on the S. maltophilia biofilms at MOI=10 (Figure 7A). One explanation is that 
at a lower titer the host has enough time to begin to form phage-resistant biofilms. A higher titer 
of phages kills more cells before biofilm formation is underway, whereas a lower titer of phages 
allows more cells to begin to establish biofilms on the polyvinyl chloride surface. 
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Potential Use in Therapy 
At the time of writing this thesis, no S. maltophilia phages have been used in any form of 
therapy. There is still much more information needed to determine if this phage should be 
recommended therapeutically. First, it will be necessary to confirm that the phage is lytic. At this 
point, the phage has not been definitively shown to be lytic or lysogenic. This is a significant 
consideration because lysogenic phages are not considered good candidates for phage therapy. 
Lysogenic phages can convert hosts into lysogens, preventing these hosts from undergoing 
immediate lysis and making the host phage-resistant (Casey et al., 2018). 
Lysogens can also result in other phenotypic changes to their host that may enhance host 
virulence. For example, the Liverpool Epidemic Strain of P. aeruginosa contains multiple 
prophages that have been shown to confer enhanced virulence to their host (Salunkhe et al., 
2005). In the same way, the Vibrio phage CTXphi carries the cholera toxin, which is required for 
the pathogen, Vibrio cholerae, to trigger toxin-mediated epidemic cholera (Waldor and 
Mekalanos, 1996). 
A similar but separate concern in identifying phages useful in therapy is the horizontal 
gene transfer of virulence factors such as toxins (Pirnay et al., 2015). Genome sequencing may 
also allow us to rule out phages that carry toxins or antibiotic resistance factors. Even if a phage 
is not lysogenic, it may be risky to introduce a genetic element that could exacerbate an 
infection. Many bacteria, including S. maltophilia, are naturally competent and able to take up 
DNA from their environment (Berg and Martínez, 2015). Therefore, there is a risk that virulence 
genes could be acquired from a phage without lysogenic conversion. 
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Phage Resistance of Biofilms 
The steps towards effective therapies require evidence of the efficacy of a phage treatment. This 
research has shown that biofilm formation is significantly affected by S. maltophilia phage Bfi1. 
However, the biofilm experiments in this thesis were performed in vitro, and in a patient, S. 
maltophilia biofilms may respond differently to phage treatment. Research on other bacterial 
pathogens indicate that biofilms may demonstrate resistance to phage. An in vivo mouse study 
using P. aeruginosa strain PAK demonstrated that a phage treatment 2 h post-infection resulted 
in 100% survival. However, this survival rate dropped down to 20% at 6 h post-infection 
(Debarbieux et al., 2010). The data in this study suggest that immature biofilms may be more 
susceptible to phage than fully developed mature biofilms. Therefore, it is important to design a 
therapy that anticipates the different stages of a biofilm. Future research with the S. maltophilia 
phage Bfi1 can address this by assessing the phage’s effect on a mature biofilm, or through a 
time-course study of biofilm development. 
There are a few reasons to explain why a biofilm might confer viral resistance. In some 
cases, biofilms cause phage resistance by preventing phage from reaching the host cells. 
Between the lytic T7 phage and its host E. coli biofilm, the protection from phage was due to 
prevention of phage transport into the biofilm and through competitive inhibition of the phage 
receptor by curli polymers (an amyloid fiber network) (Vidakovic et al., 2017). In other words, 
the phage was adhering to the extracellular polymers instead of adsorbing to the cells. 
Phase variation observed during biofilm maturation may also be involved in phage 
resistance. Phase variation involves changes of protein expression within a bacterial population. 
As the biofilm-forming phenotypes will involve changes in the proteins expressed on the cell 
surface, the proteins required for adsorption may not be present on cells within a biofilm. As an 
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example of phase variation resistance, Bordetella species is 106 times more susceptible to phage 
BPP1 when pertactin, an adhesion protein, is expressed (Liu et al., 2002). This protein is 
expressed in much higher quantities during the virulent phase, when certain adhesins, toxins, and 
secretion systems are activated (Liu et al., 2002).  
 
Phage Therapy 
The research on phage therapy for treatment of bacterial infections has grown substantially in 
recent years. S. maltophilia phage Bfi1 may be useful in such treatments. While it may not 
demonstrate a broad host range, this phage could be tested in combination with other approaches 
to treat Stenotrophomonas infections. 
Using multiple phages in a phage cocktail (termed polyphage therapy) may offer benefits 
that a monophage treatment cannot. Use of phage cocktails can solve two difficulties presented 
to clinicians: the limited host range and the development of phage resistance. By combining 
multiple phages that each have a different host range, there are greater chances that a strain of 
bacteria will be susceptible to one or more of the phages in the cocktail. For example, Alves et 
al. (2015) reported that a phage cocktail in vitro led to 100% inhibition of Pseudomonas PAO1 
after 24 h. In contrast, Pseudomonas PAO1 began re-growing after 8 h following each 
monophage treatment. Phage resistance can evolve naturally among host bacteria through genetic 
mutation, but using multiple phages should reduce the possibility that bacterial mutants become 
multi-phage resistant. 
It is important to acknowledge that polyphage therapy is not a perfect solution. In a study 
by Gu et al. (2012), the authors demonstrated the development of phage-resistant mutants of 
Klebsiella pneumoniae strain K7, even when treated with a three phage cocktail. It should be 
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noted that regrowth of K. pneumoniae from individual phage treatments was detected between 6-
8 h, while regrowth from the phage cocktail occurred at 26 h. Although phage-resistance remains 
a concern in polyphage therapy, it is greatly reduced. 
Another consideration, which was highlighted earlier, is that not all phages are 
innocuous. Some bacterial viruses can enhance the virulence of their hosts. This same concern 
exists and could be heightened in polyphage treatments. For example, one phage may confer 
resistance to other phages in a cocktail. This concern can be alleviated by requiring substantial 
characterization of prospective phages prior to their application. Bioinformatic techniques, which 
allow for rapid identification of undesirable genetic elements, can begin to eliminate phages from 
use that possess such characteristics (Chan et al., 2013).  
Another emerging approach to phage therapy is the combination of phages with 
antibiotics to enhance phage virulence. The addition of a low dosage of the cephalosporin, 
cefotaxime with Escherichia phage phiMFP results a seven-fold increase in burst size compared 
to the phage by itself (Comeau et al., 2007). This phenomenon, referred to as phage-antibiotic 
synergy (PAS), has been demonstrated in phages of P. aeruginosa and Burkholderia cepacia 
complex, as well (Knezevic et al., 2013; Kamal and Dennis, 2015). It is difficult to identify the 
benefit and drawbacks for this approach currently, due to the limited data available.  
In the United States, the pathway for phage therapy development includes a series of 
steps that have not yet been surmounted. The current process for the development of 
conventional medicinal products may not be compatible with timely phage therapy development 
(Pirnay et al., 2015). But most experts can agree that phages used in therapies require a complete 
characterization of their physiology, genetics, and pharmacological potential (Forde and Hill, 
2018). Only after these steps, should the production and regulation of a therapy be considered. 
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Conclusion 
There are still important research questions that must be addressed before we can 
definitively recommend this phage for such a therapy. We need to show that the phage is lytic, 
that its genome does not carry virulence factors, and demonstrate that it can be useful in treating 
biofilms, either by itself or in combination with other phages or antibiotics. With a growing 
prevalence of S. maltophilia infections, and the steady rise of antibiotic resistance, there is an 
urgent need for alternative treatments of this pathogen.  
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